Canaccord reiterates Natera stock rating on strong Q3 results
Canaccord Genuity reiterated a Buy rating and $500 price target on Natera (NTRA) after strong Q3 2026 results. Revenue rose 34% YoY to $794M, and the company raised its 2026 revenue outlook to $3.005B-$3.035B. Despite this, shares fell 12.2% over the past week. Natera also announced a new CEO and a $6B revenue target for 2029.
How this was made
The 30-second read
Why it matters
Earnings beat and raised guidance may drive short‑term buying pressure, but higher operating expenses could temper enthusiasm.
Market read
Natera's earnings beat and upgraded outlook provide a fresh catalyst for traders, with potential upside in the biotech sector.
What to watch
Execution risk in scaling the Signatera platform and potential cash burn from expanded R&D.
Background
Canaccord Genuity reiterated a Buy rating and $500 price target for Natera after its Q3 earnings release.
Ticker impact
Natera reported Q3 2026 results beating estimates and raised its 2026 revenue outlook to $3.005‑$3.035 billion, prompting Canaccord to reiterate a Buy rating with a $500 price target.
potential upside as the market prices in the raised revenue guidance and analyst buy rating
Strong revenue growth, improved margins, and a $500 target suggest investors may bid the stock higher despite recent week‑long decline.
Market effects
Positive signal for the genetic‑testing and diagnostics sector as Natera's results exceed expectations.
U.S. biotech market may see modest uplift from the earnings beat.
Limited to investors focused on U.S. biotech; no broader macro effect.
Counterpoint
The stock's 12% weekly decline and higher expense guidance could weigh on near‑term performance.
Key entities
- companyNatera Inc.
Genetic testing and diagnostics firm reporting Q3 2026 results.
- analystCanaccord Genuity
Equity research firm that reiterated a Buy rating on Natera.
